Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C21H26ClN3OS
CAS Number:
Molecular Weight:
403.97
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
200-381-5
MDL number:
Form:
powder
Quality level:
form
powder
Quality Level
originator
Schering Plough
storage temp.
2-8°C
SMILES string
ClC(C=C1)=CC2=C1SC3=CC=CC=C3N2CCCN4CCN(CCO)CC4
InChI
1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2
InChI key
RGCVKNLCSQQDEP-UHFFFAOYSA-N
Gene Information
human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), ADRA2A(150), ADRA2B(151), ADRA2C(152), DRD2(1813), OPRS1(10280)
General description
Perphenazine is an antipsychotic drug used in treating schizophrenia. It modulates antioxidant levels and helps in the management of oxidative injury in schizophrenia. However, it is less effective than the clozapine drug group in improving response to oxidative injury.
Biochem/physiol Actions
D2 dopamine receptor antagonist; α-adrenergic receptor antagonist and σ-receptor agonist; phenothiazine antipsychotic. Inhibits glutamate dehydrogenase in vitro.
Features and Benefits
This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under Perphenazine
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Skin Sens. 1
Storage Class
11 - Combustible Solids
wgk
WGK 3
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Angela M Koranek et al.
Schizophrenia research, 137(1-3), 137-140 (2012-03-01)
Results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) indicate that, with the exception of olanzapine, no substantial overall differences were identified between second generation antipsychotics (SGAs) and the first generation antipsychotic (FGA) perphenazine. This study evaluated the effect
Donald E Addington et al.
The Journal of clinical psychiatry, 72(1), 75-80 (2010-09-28)
According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the
Elina Turunen et al.
The Journal of pharmacy and pharmacology, 63(1), 19-25 (2010-12-16)
The sublingual administration route as well as solid dispersion formation with macrogol 8000 and complexation with β-cyclodextrin (β-CyD) were investigated as ways for improving the absorption of perphenazine, a poorly water-soluble drug subjected to substantial first-pass metabolism. The absorption of
